Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Thoracic Neoplasms 1Neoplasms 1Lung Neoplasms 1Lung Diseases 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Bronchogenic 1Bronchial Neoplasms 1

Interventions

Carboplatin 6Pemetrexed 4pembrolizumab 3Cisplatin 3Paclitaxel 2Gemcitabine 2Docetaxel 2zipalertinib 1zimberelimab 1sacituzumab govitecan 1pralsetinib 1patritumab 1camrelizumab 1alectinib 1Vinorelbine 1Thrombin 1Talc 1TachoSil 1TNFSF10 protein, human 1Surveys and Questionnaires 1Nivolumab 1Injections 1Fibrinogen 1Erlotinib Hydrochloride 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Lung Diseases × TNFSF10 protein, human × Clear all
NCT03083743 2017-03-20

A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection

Shanghai Gebaide Biotechnology Co., Ltd.

Phase 3 Unknown
417 enrolled
Thoracic

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡